Kornimate/medical-research-clean huggingface dataset:
the effect of nexium and probiotics on insulin secretion and cardiovascular risk factors in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: to test the effect of nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients. study hypothesis: 1. nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of hba1c 2. probiotics changes the gut flora and bloodpressure 3. probiotics causes a change in inflammation and thrombosis.


Eligibility criteria:
inclusion criteria: * type 2 diabetes (who criteria) treated with metformin and/or sulfonylureas or diet * males and females between 40 and 70 years * hba1c between 6,0-10,0 * diabetes duration \> 1 year exclusion criteria: * kidney disease (s-creatinine above the upper limit of normal range). * liver disease (alat increase \> 3 times the upper limit of the normal range of alat). * macroalbuminuria (urinary albumin excretion of \> 300 mg/day). * heart failure(nyha class lll or lv) * severe neuropathy (symptoms + vibration perception threshold \> 50 measured by biothesiometer.) * neutropenia (neutrophil count\<2.0x10/l) or anemia (hemoglobin\<8mm for men or \<7mm for women. * alcohol abuse * drug abuse * severe organic or metabolic diseases including cancer * c-peptide\< 0,3 pmol/l * medicine interaction * treatment with insulin * ppi or other medications for ulcus diseases * treatment with warfarin or other coumarin derivations * pregnant or breastfeeding women * allergy to medication used in the study * participants may not participate in another clinical intervention trial
staphvax immunogenicity in orthopedic implant patients

Conditions: Staphylococcal Infections; Joint Prosthesis

Summary: s. aureus is the most common pathogen involved in prosthetic joint infection. staphvax® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of s. aureus to a carrier protein. it is currently being evaluated for future licensing. this study aims to demonstrate the safety and immunogenicity of a single dose of staphvax in patients who are candidates for knee or hip arthroplasty.


Eligibility criteria:
inclusion criteria: * age 18 years or older * candidate for knee or hip replacement * expectation of protocol compliance * negative pregnancy test, where appropriate exclusion criteria: * known s. aureus infection in the prior 3 months * infection in the prior 2 weeks * known hiv infection * immunomodulatory drugs * malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer) * hypersensitivity to components of staphvax

Keywords: vaccine staphylococcus aureus vaccine
a phase ii uncontrolled study of bay73-4506 in previously untreated patients with metastatic or unresectable rcc

Conditions: Carcinoma, Renal Cell

Summary: this is a uncontrolled, open-label, non-randomized phase ii study of oral bay73-4506 to evaluate the response rate of bay73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (rcc).

the final analysis of efficacy will be performed after last patient has been treated for at least 6 months. additional periodic safety and efficacy data reviews will be performed for any patients continuing to receive study drug afterwards.

Eligibility criteria:
inclusion criteria: * male or female patients \>/= 18 years of age. * patients, who suffer from unresectable and/or metastatic, measurable predominantly clear cell rcc (renal cell carcinoma histologically) or cytologically documented. * patients must be previously untreated for advanced disease. prior palliative radiation therapy is allowed if the target lesion(s) are not included within the radiation field and no more than 30% of the bone marrow is irradiated. * patients who have at least one uni-dimensional measurable lesion by computed tomography (ct-scan) or magnetic resonance imaging (mri) according to response evaluation criteria in solid tumors (recist). * patients with "intermediate" or "low" risk per the motzer score. * patients who have an eastern co-operative oncology group (ecog) performance status of 0 or 1. * adequate bone marrow, renal and hepatic function as assessed by the following laboratory requirements to be conducted within 7 days prior to study drug treatment exclusion criteria: * patients who have received prior systemic treatment regimens for rcc. * uncontrolled/unstable cardiac disease * uncontrolled hypertension * active clinically serious infections (\> common terminology criteria for adverse events \[ctcae\] grade 2 ) * history of human immunodeficiency virus (hiv) infection or chronic hepatitis b or c. * known history or symptomatic metastatic brain or meningeal tumours * patients with seizure disorder requiring medication * patients with evidence or history of bleeding diathesis. any hemorrhage or bleeding event \>/= ctcae grade 3 within 4 weeks of first dose of study. * pregnant or breast-feeding patients

Keywords: renal cell carcinoma
the effect of rosuvastatin and olmesartan on the progression of coronary atherosclerotic disease

Conditions: Coronary Syndrome

Summary: 1. stains have demonstrated consistent benefits to reduce cardiovascular events in several primary and secondary prevention trials. the suppression of plaque progression or regression may be a part of mechanism of clinical benefit. the intravascular ultrasound studies demonstrated that intensive statin therapy can regress or inhibit the progression of coronary atherosclerosis. 2. unregulated renin-angiotensin system is important in the pathogenesis of cardiovascular disease. angiotensin receptor antagonists (arb) have been reported to improve clinical outcomes in patients with heart failure, left ventricular dysfunction, myocardial infarction, and high-risk patients. several small studies showed that arbs were effective to inhibit the progression of coronary atherosclerosis by intravascular ultrasound examination. 3. the combined therapy with statins and arbs may be additive or synergistic effects on the atherosclerosis regression as well as to improve endothelial dysfunction and insulin resistance in addition to lowering cholesterol levels and blood pressure when compared with either monotherapy in patients. 4. serial computed tomography angiography (cta) can be utilized to assess the effect of treatment on coronary plaque morphology. in addition to the assessment of luminal stenosis, cta also allows characterization of plaque morphology.


Eligibility criteria:
inclusion criteria: 1. subjects must be at 19 years\~70 years of age 2. patients undergoing coronary cta with coronary artery stenosis 30\~70% 3. informed consent 4. appropriate ct resolution enough to measure of plaque volume 5. patients who are stain and renin-angiotensin system blocker naïve at least for 1 year exclusion criteria: 1. patients with\>=70% luminal stenosis or requiring percutaneous coronary intervention(pci) 2. severely calcifiedcoronary artery 3. patients who have a history of previous pci or coronary artery bypass grafting surgery.
re-stop dvt: reload of high dose atorvastatin for preventing deep vein thrombosis in statin users

Conditions: Thrombosis; Prevention; Surgery

Summary: reload of high dose statin may have potential for preventing deep vein thrombosis (dvt) in patients on statin undergoing total knee replacement arthroplasty. a body of evidence have been reported that reloading of atorvastatin have efficacy in reducing periprocedural myocardial infarction and contrast induced nephropathy. these effects are considered to be mainly due to their antioxidant anti-thrombotic and anti-inflammatory property. we, therefore, hypothesize that high dose atorvastatin re-loading may prevent dvt.


Eligibility criteria:
inclusion criteria: * patients who are going to receive total knee replacement arthroplasty from any cause. * \< 19 years old exclusion criteria: * patients with cancer * patients receiving anticoagulant agents from any cause * current statin users * expecting survival from other co-morbidity \< 1year * bed ridden patient * ast, alt \> 3times of upper normal limit * ck\> upper normal limit * pregnancy * patients who receives hormone replacement therapy

Keywords: statin vein
risk factors for rebleeding in patients with obscure gastrointestinal bleeding

Conditions: Gastrointestinal Bleeding

Summary: the investigators investigated the rebleeding rate the risk factors for rebleeding after long-term follow-up (≥12 months) in patients who underwent capsule endoscopy for obscure gastrointestinal bleeding.


Eligibility criteria:
inclusion criteria: * patients who underwent capsule endoscopy in shanghai renji hospital(china) from june 2002 to january 2012 for obscure gastrointestinal bleeding exclusion criteria: 1. patients who did not undergo a gastroscopy and colonoscopy performed before capsule endoscopy examination; and 2. patients with follow-up examination for other know clinical diseases.

Keywords: capsule endoscopy obscure gastrointestinal bleeding rebleeding risk factors
treatment of symptomatic pes planus by sinus tarsi screw versus conical subtalar screw arthroereisis

Conditions: Symptomatic Flexible Flat Feet

Summary: compare the outcome of surgical treatment planus by sinus tarsi screw versus conical subtalar screw arthroereisis

pes planus occurs as a result of loss of the medial longitudinal arch, abduction of the forefoot and excessive subtalar eversion. it can broadly be categorized as rigid or flexible.(1) flexible pes planus has no single identifiable cause and is often asymptomatic.(1-3) patients with pesplanus had a very tight achilles tendon due to compensatory motion.(4) it can become painful and may require orthopaedic or pediatric intervention. common treatment modalities include rest, physiotherapy, orthotics and anti-inflammatories.(1,3,5-6) surgery is uncommon unless pain persists in spite of nonsurgical management.(5-6) surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.(1,2,6-9) fusion of selected joints in the foot is not recommended in paediatric patients unless associated with a neuromuscular pathology.(1,5) subtalar arthroereisis is a recognized non-fusion surgical treatment for symptomatic paediatric flexible pes planus. arthroereisis (also arthroreisis, arthrorhisis or arthrorisis) derives from greek, translated as to prop up or support a joint.(10) when flexible pes planus becomes symptomatic, affecting gait and limiting quality of life, and conservative treatment such as weight reduction, physiotherapy or insoles fail, operative treatment can be considered .(7) there are two techniques for subtalar arthroereisis: (11) insertion of an implant directly into the sinus tarsi to prevent it collapsing down. (10) screw insertion into the lateral side of either the talus or calcaneus(12). calcaneo-stop method with cancellous screw insertion into sinus tarsi for subtalar arthroresis is a valid procedure for this multiplanar deformity. maintaince of correction of the deformity is achieved via a prioprioceptive mechanism. (13) the current research is the first one to compare the clinical , radiological,and patient satisfaction outcome of planovalgus cases treated with two different types of subtalar arthroereisis implants . the purpose of this prospective study is to show the best technique to achieve patient satisfaction.

Eligibility criteria:
inclusion criteria: - patients are eligible for participation in the study if * patients above the ages of 7years * all patients with symptomatic pes planus * flexible flat feet * not respond to conservative therapies. exclusion criteria: * patients are excluded for participation in the study if * patients were age \< 7 years * asymptomatic patient * rigid flat feet * unfit for surgery * children with neuromuscular diseases, post traumatic or congenital pes planovalgus will be excluded from the study
use of bromhexine and hydroxychloroquine for treatment of covid-19 pneumonia

Conditions: Covid-19

Summary: in the current situation it is of great importance to discover a safe, cost-effective and available treatment strategy in order to limit the rapidly spreading sars-cov-2. recent studies have shown that hydroxychloroquine could have a role in the treatment of infected patients. it is however not very likely that hydroxychloroquine alone could be adequate for treatment of covid-19 disease. effective therapy that prevents the virus entrance should contain at least tmprss2 inhibitor or a competitive inhibitor of viral ace 2 binding. the use of bromhexine at the dose adequate to selectively inhibit the tmprss2, resulting in preventing of viral entrance via tmprss2-specific pathway, coud be an effective treatment of covid-19. in our study we would like to explore the therapeutic potential of bromhexin and hydroxychloroquine in covid-19 patients. hypothesis 1. combined treatment with bromhexin and hydroxychloroquine shortens the course of disease in hospitalized covid-19 patients compared to hydroxychloroquine alone. 2. combined treatment with bromhexin and hydroxychloroquine lowers the incidence of secundary pulmonary infections in hospitalized covid-19 patients compared to hydroxychloroquine alone. 3. combined treatment with bromhexin and hydroxychloroquine decreases the need for icu admission in hospitalized covid-19 patients compared to hydroxychloroquine alone.


Eligibility criteria:
inclusion criteria: * age \> 18 years, * confirmed infection (positive pcr from nasopharyngeal swab), * fullfilled hospital admission criteria exclusion criteria: * pregnancy, * known allergy for bromhexine or hydroxychloroquine, * epilepsy, * prolonged qtc interval, * child c liver disease, * dementia, * psychoorganic syndrome, * terminal chronic disease
a study to assess the efficacy and safety of asp1941 in combination with metformin in asian diabetes patients

Conditions: Type II Diabetes Mellitus

Summary: to compare the efficacy and safety of asp1941 + metformin with metformin alone in asian subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * diagnosed as type 2 diabetes mellitus patient at least 12 weeks before the study * stable diet and exercise program for at least 8 weeks before the study * on a stable dose of at least 1500 mg/day metformin monotherapy or at least 1000 mg/day metformin monotherapy for the subject who can not titrate up to 1500 mg/day due to safety concern of metformin * bmi of 20.0 to 45.0 kg/m2 * a hba1c value between 7.0 and 10.0% at screening and does not meet any of discontinuation criteria on fasting plasma glucose exclusion criteria: * type 1 diabetes mellitus * proliferative diabetic retinopathy * receiving insulin within 12 weeks prior to the study * history of clinically significant renal disease(s) * significant dysuria caused by a neurogenic bladder or a benign prostate hypertrophy etc. * urinary tract infection or genital infection * continuous use of systemic corticosteroids, immunosuppressants, or loop diuretics * history of cerebrovascular attack, unstable angina, myocardial infarction, angioplasty, serious cardiac diseases within 12 weeks prior to the study * severe infection, serious trauma, or perioperative subject * known or suspected hypersensitivity to asp1941 * history of treatment with asp1941 * participated in another clinical study, postmarketing study or medical device study within 12 weeks before the study * serum creatinine value exceeding the upper limit of normal range * urinary microalbumin/urinary creatinine ratio \>300 mg/g

Keywords: asp1941 ipragliflozin urine glucose metformin plasma glucose
postoperative surgical site infection afterent bone flap surgery

Conditions: Rate of Infections; Operating Site; Post-operative Surgery; Bone Flap Surgery; Otolaryngology

Summary: in 2017, the french society in anesthesia and reanimation published new recommendations on intraoperative antibiotic prophylaxis. now, no more than 48 hours of antibiotic prophylaxis applies to any otolaryngology surgery, regardless of patient's medical history or type of flap used to rebuild. this has resulted in an alignment of our local protocol in croix-rousse hospital. however, after few years, our local impressions are that bone flap surgeries are very likely to provide surgical site infections (osteo-articular or non-osteo-articular infections). the prejudice of these postoperative site infections is significant, with serious consequences,. of both functional and aesthetic sides. we wanted to objectify this impression by retrospectively analyzing the data relating to patients operated on for bone flapsurgeries. knowing the operation site infection rate after surgery for otolaryngology bone flap surgery will allow us to objectively understand the infectious risk of these surgeries, in particular the risk of osteoarticular infection. identifying operation site infection factors will allow us to better target and prevent them. the goal is to find out if the antibiotic prophylaxis currently recommended is sufficient and effective for this type of surgery.


Eligibility criteria:
inclusion criteria: * patient operated for bone flap in croix-rousse hospital, in otorhinolaryngology department, since september 2012 and until january 2019 exclusion criteria: * patient's opposition to participate in the study

Keywords: bone flap surgery postoperative surgical infection
circadian variations in ocular blood flow in glaucomatous and normal eyes

Conditions: Glaucoma, Open-Angle; Circadian Rhythm; Intraocular Pressure; Regional Blood Flow

Summary: after focusing many years only on intraocular pressure (iop) as the primary risk factor, recently the impact of ocular blood flow is getting more consideration for the pathophysiology of glaucoma. the circadian change of intraocular pressure (iop) is well investigated, but diurnal variations in ocular blood flow are yet to be evaluated, especially in glaucomatous eyes. this study is performed to investigate circadian variation of ocular blood flow assessed by laser interferometric fundus pulsation amplitude (fpa) and laser doppler flowmetry (ldf) in glaucomatous eyes during topical antiglaucoma therapy at 8:00, 12:00, 17:00 and 21:00, to compare these circadian variation of ocular blood flow in glaucomatous eyes with variations in healthy eyes and to relate blood flow variations with iop variations.


Eligibility criteria:
inclusion criteria: for the glaucoma patients: * medical controlled primary open angle glaucoma with a history of more than 2 years * topical medication with beta-blockers (timolol, betaxolol, levobunol) * iop with medication \ 22 mmhg) * visual field testing: mild glaucomatous defects (humphrey 30-2 with md\>10) * optic nerve head: c/d-ratio between 0.4 and 0.9 * ametropy \< 3 dpt * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant for the age matched control subjects: * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings, ametropy \< 3 dpt. exclusion criteria: for the glaucoma patients: * history of trabeculectomy or laser trabeculoplasty * any other ocular disease with possible vascular involvement such as diabetic retinopathy, age related macular disease, retinal vein or artery occlusion. * uncontrolled systemic hypertension (defined as systolic blood pressure \> 170 mmhg or diastolic blood pressure \> 100 mmhg) * diabetes mellitus for the age matched control subjects: * abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * symptoms of a clinically relevant illness in the 3 weeks before the first study day * history or presence of gastrointestinal, liver or kidney disease * ametropy \> 3 dpt

Keywords: laser doppler flowmetry choroidal blood flow fundus pulsation amplitude intraocular pressure
treadmill training in people with parkinson's disease

Conditions: Parkinson Disease

Summary: the study will explore if coupling speed and cadence during treadmill training elicit more benefits than controlling speed alone in individuals with parkinson's disease.

impaired gait is prevalent and raises the fall risk in people with parkinson's disease (pwpd). gait speed, step length, and cadence are three interrelated components of human gait, as speed is determined by step length and cadence. auditory cues, such as metronomes, have been shown to aid training for pwpd. the purpose of this study is to examine if controlling cadence and speed improves overground gait parameters in pwpd better than only controlling speed. two groups of pwpd will participate. both groups will attend a single treadmill training session. both groups will complete overground walking trials as a pre-test measurement. one group will receive treadmill training in which cadence, via a metronome, and speed are controlled, while only speed is controlled for the other group. both groups will complete the same overground walking trials as a post-test measurements. the specific aim of this study is to determine the effects of metronome cues and gait speed versus gait speed alone treadmill training on spatiotemporal gait parameters when walking overground in pwpd.

Eligibility criteria:
inclusion criteria: * can read and understand english * between the ages of 18-89 years old * diagnosed with parkinson's disease * stage 1-3 based on the hoehn and yahr * able to walk overground more than 15m independently * able to walk on a treadmill for at least 15 minutes independently exclusion criteria: * diagnosed with any uncontrolled cardiorespiratory or metabolic disease * experience any other known neurologic disorders that affect their ability to walk * diagnosed with any visual or communication disorders * suffered a lower extremity injury within the last 6 months
group balance training for people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: people with multiple sclerosis (ms) often have affected balance capacity and an increased risk for falls. a risk factor for falls are activities requiring dual attention. another factor leading to reduced balance capacity is trunk stability, and decreased trunk stability has been seen in people with ms compared to healthy controls. earlier studies using core stability exercises have shown positive effects on balance, compared to no training. in sweden, physical therapy for people with ms has often included group training. however, evidence for this intervention is scarce. the aim of this study is therefore to investigate balance training in group. the balance training includes core stability exercises and dual attention activities. a multi-centre study is planned with a waiting-list design. participants are randomised to either exercise group with early start or with late start. the group balance training includes training 60 minutes 2 times per week for 7 weeks.


Eligibility criteria:
inclusion criteria: * diagnosed multiple sclerosis by a neurologist, being able to walk 100 m with or without walking device, being able to get down on the floor with minor assistance exclusion criteria: * no balance deficit here defined as being able to stand still heel-toe for 30 seconds with arms crossed. * ongoing relapse, cognitive- or language difficulties that prohibits performing the outcome measures.

Keywords: multiple sclerosis physical therapy postural control